Dimethyl fumarate: targeting glycolysis to treat MS
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Fumarate inhibits a variety of α-KGDDs.
“As mentioned, fumarate also inhibits a variety of α-KGDDs, enzymes involved in multiple cellular processes, from metabolism to signalling and epigenetics90-92”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [91]
Fumarate acts as a powerful inhibitor of the TET family of DNA demethylases and of a series of histone demethylases.
“Recent data demonstrated that fumarate acts as a powerful inhibitor of the TET family of DNA demethylases and of a series of histone demethylases91,92.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 10 · Cited by 27
Research works printed but not linked: 1
- Mills, E. A., Ogrodnik, M. A., Plave, A. & Mao-Draayer, Y. Front. Neurol. 9, 5 (2018).
- Authors
- Angiari, S., & O’Neill, L. A.
- Affiliations
- Trinity College Dublin (IE)
- Corresponding author
- Angiari, Stefano
- ORCID
- Angiari, Stefano
- Venue
- Cell Research
- Published
- 2018-05-29
- Volume
- 28
- Issue
- 6
- Pages
- 613-615
- ISSN
- 1001-0602 (ISSN-L)
- 1748-7838
- PMC
- PMC5993828
- OpenAlex
- W2806578739
- Cited by
- 27
- References
- 10
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 2
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cell Research (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust (109443/Z/15/Z)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- dimethyl fumarate, multiple sclerosis, glycolysis, glyceraldehyde-3-phosphate dehydrogenase, post-transcriptional modification, immune cell activation, immunomodulators, psoriasis, inflammation
- MeSH terms
- Dimethyl Fumarate, Administration, Oral, Glycolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
